120 related articles for article (PubMed ID: 29578172)
1. Effect of bevacizumab combined with chemotherapy at different sequences in the gastric-cancer-bearing nude mice.
Lv Y; Song L; Chang L; Zhang X; Liu Y; Liu W
J Cancer Res Ther; 2018; 14(Supplement):S190-S196. PubMed ID: 29578172
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab followed by chemotherapy is potential therapy for gastric cancer.
Lv Y; Song L; Chang L; Liu Y; Zhang X; Wang Y; Wang L; Liu W
J BUON; 2016; 21(6):1466-1470. PubMed ID: 28039709
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of bevacizumab monoclonal antibodies in combination with chemotherapy in different time sequences on a human gastric carcinoma cell line.
Lv Y; Song L; Chang L; Liu Y; Zhang X; Li Q; Zhou X; Liu W
Ir J Med Sci; 2017 May; 186(2):275-280. PubMed ID: 27351431
[TBL] [Abstract][Full Text] [Related]
4. [Screening for predictive biomarkers of bevacizumab treatment in gastric cancer subcutaneous xenografts].
Zhang Q; Xu J; Ye J; Yuan Y; Chen J; Peng J; He Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Feb; 18(2):177-80. PubMed ID: 25656129
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
Greening DW; Lee ST; Ji H; Simpson RJ; Rigopoulos A; Murone C; Fang C; Gong S; O'Keefe G; Scott AM
Oncotarget; 2015 Nov; 6(35):38166-80. PubMed ID: 26517691
[TBL] [Abstract][Full Text] [Related]
6. Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.
Sakurai Y; Uraguchi T; Imazu H; Hasegawa S; Matsubara T; Ochiai M; Funabiki T
Gastric Cancer; 2004; 7(2):110-6. PubMed ID: 15224198
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
Mueller T; Freystein J; Lucas H; Schmoll HJ
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model
Wang M; Zeng Q; Li Y; Imani S; Xie D; Li Y; Han Y; Fan J
J Drug Target; 2020 Nov; 28(9):961-969. PubMed ID: 32374627
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
Oliva P; Decio A; Castiglioni V; Bassi A; Pesenti E; Cesca M; Scanziani E; Belotti D; Giavazzi R
Br J Cancer; 2012 Jul; 107(2):360-9. PubMed ID: 22713663
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts.
Tai CJ; Wang H; Wang CK; Tai CJ; Huang MT; Wu CH; Chen RJ; Kuo LJ; Wei PL; Chang YJ; Chang CC; Chiou HY; Wu CJ
Clin Exp Med; 2017 May; 17(2):141-150. PubMed ID: 26995061
[TBL] [Abstract][Full Text] [Related]
11. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of combination chemotherapy with 5-FU, CDDP and CPT-11 for human gastric carcinoma transplanted into nude mice - comparative study of in vivo chemosensitivity test].
Kanamori N; Fujii M; Kochi M; Kaiga T; Takahashi T; Takayama T
Gan To Kagaku Ryoho; 2007 Jun; 34(6):881-4. PubMed ID: 17565250
[TBL] [Abstract][Full Text] [Related]
13. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of combination chemotherapy with 5-FU and CDDP for human gastric carcinoma transplanted into nude mice].
Yamada T; Tanase M; Watanabe A; Sawada H; Yamada Y; Shino Y; Yamashita J; Matsuda M; Nakano H
Gan To Kagaku Ryoho; 1997 Jan; 24(1):43-7. PubMed ID: 9020944
[TBL] [Abstract][Full Text] [Related]
15. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
Bozec A; Sudaka A; Etienne-Grimaldi MC; Brunstein MC; Fischel JL; Milano G
Oral Oncol; 2011 Oct; 47(10):940-5. PubMed ID: 21862388
[TBL] [Abstract][Full Text] [Related]
17. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance.
Yoon C; Park DJ; Schmidt B; Thomas NJ; Lee HJ; Kim TS; Janjigian YY; Cohen DJ; Yoon SS
Clin Cancer Res; 2014 Aug; 20(15):3974-88. PubMed ID: 24947926
[TBL] [Abstract][Full Text] [Related]
18. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
19. [Impacts of Bevacizumab on vascular endothelial growth factor and Sp1 expression in gastric cancer xenografts].
Zhou CF; Ji J; Yuan F; Yu YY; Liu BY; Zhang J; Zhu ZG
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):180-4. PubMed ID: 22368029
[TBL] [Abstract][Full Text] [Related]
20. Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
Chen YF; Yuan A; Cho KH; Lu YC; Kuo MY; Chen JH; Chang YC
PLoS One; 2017; 12(11):e0187824. PubMed ID: 29121075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
